logo
  • About Initiator Pharma
    • Mission
    • Scientific and Clinical Advisory Board
    • Goals, strategy and business model
    • CEO Letter
    • History
  • Science
    • Pipeline
      • IPED2015 Clinical Program
      • IP2018 Clinical Program
      • IPTN2021 Clinical Program
      • IP2017 Program* (preclinical)
      • IP2016 Program* (preclinical)
    • Technology & Therapeutic Areas
      • Erectile Dysfunction
      • Depression
      • Trigeminal Neuralgia
  • Governance
    • General Meetings
    • Management
    • Board of Directors
    • Auditing
    • Articles of Association
    • Remuneration and incentive program
  • Investors
    • Investment case
    • Reports and Presentations
    • The Share
    • Ownership Structure
    • Analyst and Media Coverage
    • Financial Calendar
    • Prospectuses
    • Press Releases
    • Subscribe
    • Certified Adviser
  • Media
    • Press Releases
    • Event Calendar
    • Subscribe
  • Contact
Loading..

Investors

Press releases

  • Non Regulatory March 6, 2023 English
    Initiator Pharma completes dosing in Phase 2a trial with IP2018
  • Regulatory February 17, 2023 English
    INITIATOR PHARMA: YEAR END REPORT 2022
Older releases

Latest reports

  • INITIATOR PHARMA: YEAR END REPORT 2022
  • INITIATOR PHARMA: Q3 2022 REPORT
  • INITIATOR PHARMA: Q2 2022 REPORT
All reports

Calendar

  • May 1, 2023
    Annual Report 2022
    Add to calendar
  • May 5, 2023
    Interim Q1 2023 report
    Add to calendar
All events

Investor contact

IR Contact
IR Contact
Torgeir Vaage
ir@initiatorpharma.com

Subscribe via e-mail

Initiator Pharma Numbers

  • Expected Number of men affected by Erectile Dysfunction worldwide by 2025 322 million
  • Number of people worldwide that are diagnosed with Trigeminal Neuralgia every year: 15000
  • Men with Erectile Dysfunction who do not respond to drug therapy 40 %
  • Investors
    • Investment case
    • Reports and Presentations
    • The Share
    • Ownership Structure
    • Analyst and Media Coverage
    • Financial Calendar
    • Prospectuses
    • Press Releases
    • Subscribe
    • Certified Adviser

Share

Read more
Initiator Pharma logo
About Initiator Pharma
  • Mission
  • Scientific and Clinical Advisory Board
  • Goals, strategy and business model
  • CEO Letter
  • History
Science
  • Pipeline
    • IPED2015 Clinical Program
    • IP2018 Clinical Program
    • IPTN2021 Clinical Program
    • IP2017 Program* (preclinical)
    • IP2016 Program* (preclinical)
  • Technology & Therapeutic Areas
    • Erectile Dysfunction
    • Depression
    • Trigeminal Neuralgia
Governance
  • General Meetings
  • Management
  • Board of Directors
  • Auditing
  • Articles of Association
  • Remuneration and incentive program
Investors
  • Investment case
  • Reports and Presentations
  • The Share
  • Ownership Structure
  • Analyst and Media Coverage
  • Financial Calendar
  • Prospectuses
  • Press Releases
  • Subscribe
  • Certified Adviser
Media
  • Press Releases
  • Event Calendar
  • Subscribe
Contact

Share

Read more
  • Cookies
  • Privacy